Evidence map›Paper›PMID 29617000›Full record

SynthesisCardiorenal medicine2018

Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis.

Haroon Kamran, Eric Kupferstein, Navneet Sharma, Jocelyne G Karam, Alyson K Myers, Irini Youssef, James R Sowers, Deborah R Gustafson, Moro O Salifu, Samy I McFarlane

Open access · bronzeAbstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Cardiorenal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Statin Use and Hyperglycemia: Do Statins Cause Diabetes?Current atherosclerosis reports · 2024
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Haroon KamranDivision of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Eric KupfersteinDivision of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Navneet SharmaDepartment of Internal Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Jocelyne G KaramDivision of Endocrinology, Department of Medicine, Maimonides Medical Center, Brooklyn, New York, USA.
Alyson K MyersDepartment of Internal Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Irini YoussefDepartment of Internal Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
James R SowersDivision of Endocrinology, Department of Medicine, University of Missouri, Columbia, Missouri, USA.
Deborah R GustafsonDepartment of Neurology, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Moro O SalifuDepartment of Internal Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
Samy I McFarlaneDepartment of Internal Medicine, State University of New York Downstate Medical Center, Brooklyn, New York, USA.
SUNY Downstate Health Sciences University · USState University of New York · USMaimonides Medical Center · USUniversity of Missouri · US

Funding

RESEARCH TRAINING/EDUCATION COREP20MD006875 · NIMHD · SUNY DOWNSTATE MEDICAL CENTER · PI BROWNE, RUTH C, FRASER, MARILYN · 2012 to 2016
$5.3M
NIMHD NIH HHS P20 MD006875
6 · The paper itself

Abstract

backgroundStatins have long been prescribed for the primary and secondary prevention of cardiovascular disease (CVD) and kidney disease. Their benefits and efficacy are widely accepted in current clinical practice, but like any other therapeutic agents, they have adverse effects. One of the emerging concerns with statin therapy is the development of new-onset diabetes mellitus (NODM), a dreaded risk factor for CVD and kidney disease and widely viewed as CVD equivalent. Accumulating evidence indicates that NODM is a consequence of statin use.

methodsWe conducted a meta-analysis of studies reporting on associations between NODM and statin use. Based on strict exclusion criteria, a total of 11 studies were selected. Their data were analyzed using Comprehensive Meta-Analysis® statistical software and reported as odds ratios (OR) with 95% confidence intervals (CI).

resultsThe cumulative fixed effect for use of statin therapy and incident NODM was an OR of 1.61 (95% CI 1.55-1.68, p < 0.001). Our results suggest that statin therapy is associated with NODM, such that there is a small but significant risk of NODM among patients receiving statin for CVD prevention therapy. However, this high-risk population also has other diabetes risk factors (such as obesity and hypertension) contributing to the development of NODM.

conclusionsIt is imperative that patients on statin therapy be monitored carefully for NODM. However, it can be argued that the risk of statin therapy is offset by the multitude of cardiovascular and kidney-protective effects provided by such an important and highly effective therapeutic agent.

Indexed as

Cardiovascular DiseasesDiabetes MellitusHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKidney DiseasesRisk FactorsSecondary PreventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular diseaseKidney diseaseNew-onset diabetesStatins

Identifiers

PMID29617000
PMCPMC5968284
OpenAlexW2789360233

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.